Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include ro...
Q2 2026
Aug 14, 2026
Q1 2026
May 6, 2026
FY 2025
Mar 12, 2026
Q4 2025
Q3 2025
Nov 12, 2025